A test of vorasidenib plus lomustine for IDH-mutant glioma that has come back
Original title: VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test that is still working out the right dose.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests two drugs used together in adults whose IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary has returned.
Who this trial is for. This trial is for adults with IDH1- or IDH2-mutant glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary that has come back. It tests the drug vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary given along with lomustine: A chemotherapy you take as a capsule. You take it now and then, not every day. It lowers your blood counts weeks after a dose. That is why the doses are spaced out. See the glossary.
Where it stands. The trial has not reported results. It is checking how safe the two drugs are when given together. It is also working out the right dose of vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary to use with lomustine: A chemotherapy you take as a capsule. You take it now and then, not every day. It lowers your blood counts weeks after a dose. That is why the doses are spaced out. See the glossary. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Someone whose tumor has an IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary or IDH2 gene change may want to know this study exists. If it sounds like a fit, you could ask your care team about it. They can tell you whether a study like this makes sense for you.
What it doesn't mean: This does not mean the two drugs work better together. A trial is a test, not proven care. Joining one is not a promise that you will be helped. And it is not a cure.
Source: ClinicalTrials.gov, October 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.